In December 2023, the FDA issued a black box warning for BCMA/CD19-targeted CAR-T cell therapies following accumulating reports of T-cell malignancies, including CAR transgene-positive lymphomas, suggesting the malignant transformation of engineered T cells. The gene discussed is CD19; the disease is lymphoma.